BibTex RIS Kaynak Göster

-

Yıl 2008, Cilt: 21 Sayı: 2, 127 - 132, 24.06.2015

Cevdet Kaya Abdullah İlktaç Mustafa Güneş Metin Öztürk Hüseyin Kanberoğlu Muhammet Karaman

Öz

-

Anahtar Kelimeler

-

Kaynakça

  • Abrams P, Cardozo L, Fall M, et al. The standardization
  • of terminology of lower urinary tract function: report
  • from the Standardization Subcommittee of the
  • International Continence Society. Neurourol Urodyn
  • : 21: 167-178.
  • Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J,
  • Wein AJ. How widespread are the symptoms of an
  • overactive bladder and how are they managed? A
  • population based prevalence study. BJU Int 2001: 87:
  • -766.
  • Milson I, Stewart W, Thuroff J. The prevalence of
  • overactive bladder. Am J Manag Care 6 (Suppl. 11)
  • : S565-5573
  • Yoshimura N, de Groat WC. Neural control of lower
  • urinary tract. Int J Urol 1997: 4: 111-125.
  • De Groat WC. A neurologic basis for the overactive
  • bladder. Urology suppl. 1997: 50: 36-52.
  • Wang P, Luthin GR, Ruggieri MR. Muscarinic
  • acetylcholine receptor subtypes mediating urinary
  • bladder contractility and coupling to GTP binding
  • proteins. J Pharmacol Exp Ther 1995: 273: 959-966.
  • Yoshimura N, Chancellor MB. Current and future
  • pharmacological treatment for overactive bladder. J Urol
  • : 168:1897-1913.
  • Wein AJ. Neuromuscular dysfunction of lower urinary
  • tract and its management. In: Walsh PC, Retik AB,
  • Darracot Vaughan jr. E, Wein AJ (eds) Campell’s
  • Urology. Saunders, Philadelphia, 2002: 931-1026.
  • Madersbacher H, Rovner E. Trospium chloride: the
  • European experience. Expert Opin Pharmacother 2006:
  • :1373-1380.
  • Hofner K, Oelke M, Machtens S, Grunewald T.
  • Trospium chloride an effective drug in the treatment of
  • overactive bladder and detrusor hyperreflexia. World J
  • Urol 2001: 19: 336-343.
  • Guay DR. Clinical pharmacokinetics of drugs used to
  • treat urge incontinence. Clin Pharmacokinet 1986: 42:
  • -1285.
  • Vereecken RL. A critical view on the value of
  • urodynamics in non neurogenic incontinence in women.
  • Int Urogynecol J 2000: 11: 188-195.
  • Coyne KS, Zyczynski T, Margolis MK, Elinof V,
  • Roberts RG. Validation of an overactive bladder
  • awareness tool for use in primary care settings. Adv
  • Ther 2005: 22: 381-394.
  • Hu TW, Wagner TH, Bentkover JD, et al. Estimated
  • economic cost of overactive bladder in the United
  • States. Urology 2003: 61: 1123-1128.
  • Abrams P, Anderson KE. Muscarinic receptor
  • anragonists for overactive bladder. BTU Int 2007: 100:
  • -1006.
  • Zinner M, Gittelman M, Haris R, et al. Trospium
  • chloride improves bladder symptoms. A multicenter
  • phase III trial. J Urol 2004:171: 2311-2315.
  • Rudy D, Cline K, Harris R, et al.Multicenter phase III
  • trial studying trospium chloride in patients with over
  • active bladder. Urology 2006; 67:275-280.
  • Halaska M, Ralph G, Wiedeman A, et al. Controlled,
  • double-blind, multicenter clinical trial to investigate
  • long-term tolerability and efficacy of trospium chloride
  • in patients with detrusor instability. World J Urol 2002:
  • : 392-399.
  • Flisser A, Walmsey K, Blavias JG. Urodynamics
  • classification of patients with symptoms of overactive
  • bladder. J Urol 2003: 169: 529-533.
  • Lin LY, Yeh NH, Lin CY, Sheu BC, Lin HH.
  • Comparisons of urodynamic characteristics between
  • female patients with overactive bladder and overactive
  • bladder plus stress urinary incontinence. Urology 2004:
  • : 945-949.
  • Digesu GA, Khullar V, Cardozo L, Stefano S.
  • Overactive bladder symptoms: Do we need
  • urodynamics? Neurourol Urodyn 2003: 22: 105-108.
  • Ouslander JG. Management of overactive bladder. N
  • Engl J Med 2004: 350: 786-799.
  • Staskin DR, Wein AJ, Andersson KE, et al. Overview
  • consensus statement. Urology 2003: 61: 1128-8.
  • Alloussi S, Laval KU, Eckert R, et al. Trospium chloride
  • in patients with motor urge symptoms: A double blind,
  • randomised, multicentre, placebo controlled study. J
  • Drug Asses 1999: 2: 27-39.

AŞIRI AKTİF MESANE SENDROMU OLAN KADINLARDA TROSPIUM CHLORIDE TEDAVİSİNİN ETKİNLİĞİ

Yıl 2008, Cilt: 21 Sayı: 2, 127 - 132, 24.06.2015

Cevdet Kaya Abdullah İlktaç Mustafa Güneş Metin Öztürk Hüseyin Kanberoğlu Muhammet Karaman

Öz

Amaç: Aşırı aktif mesane sendromu bulunan kadınlarda trospium tedavisinin etkinliği ve bu etkinin ürodinamik bulgular ile ilişkisi araştırıldı. Yöntem: Aşırı aktif mesane sendromu bulunan 44 kadın hasta çalışmaya alındı. 8 haftalık trospiyum tedavisinden sonra, hastaların tedavi öncesi ve sonrası OAB-V8 semptom skoru, ürodinamik bulguları karşılaştırıldı. Bulgular: Ortalama OAB-V8 semptom skoru tedavi ile birlikte anlamlı olarak düşük bulundu (11.9±6.3; 24.9±5.1; p<0.05).Detrusor aşırı aktivitesi bulunan kadın hastaların (10.3±4.1) detrusor aşırı aktivitesi olmayan kadın hastalara (14.2+5.3) göre trospium tedavisinden daha fazla fayda gördükleri saptandı. Sonuç: Trospium tedavisi ispatlanmış detrusor aşırı aktivitesi olan kadın hastalarda daha etkili bulunmuştur. Anahtar Kelimeler: Aşırı aktif mesane, İşeme disfonksiyonu, Farmakoterapi

Anahtar Kelimeler

-

Kaynakça

  • Abrams P, Cardozo L, Fall M, et al. The standardization
  • of terminology of lower urinary tract function: report
  • from the Standardization Subcommittee of the
  • International Continence Society. Neurourol Urodyn
  • : 21: 167-178.
  • Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J,
  • Wein AJ. How widespread are the symptoms of an
  • overactive bladder and how are they managed? A
  • population based prevalence study. BJU Int 2001: 87:
  • -766.
  • Milson I, Stewart W, Thuroff J. The prevalence of
  • overactive bladder. Am J Manag Care 6 (Suppl. 11)
  • : S565-5573
  • Yoshimura N, de Groat WC. Neural control of lower
  • urinary tract. Int J Urol 1997: 4: 111-125.
  • De Groat WC. A neurologic basis for the overactive
  • bladder. Urology suppl. 1997: 50: 36-52.
  • Wang P, Luthin GR, Ruggieri MR. Muscarinic
  • acetylcholine receptor subtypes mediating urinary
  • bladder contractility and coupling to GTP binding
  • proteins. J Pharmacol Exp Ther 1995: 273: 959-966.
  • Yoshimura N, Chancellor MB. Current and future
  • pharmacological treatment for overactive bladder. J Urol
  • : 168:1897-1913.
  • Wein AJ. Neuromuscular dysfunction of lower urinary
  • tract and its management. In: Walsh PC, Retik AB,
  • Darracot Vaughan jr. E, Wein AJ (eds) Campell’s
  • Urology. Saunders, Philadelphia, 2002: 931-1026.
  • Madersbacher H, Rovner E. Trospium chloride: the
  • European experience. Expert Opin Pharmacother 2006:
  • :1373-1380.
  • Hofner K, Oelke M, Machtens S, Grunewald T.
  • Trospium chloride an effective drug in the treatment of
  • overactive bladder and detrusor hyperreflexia. World J
  • Urol 2001: 19: 336-343.
  • Guay DR. Clinical pharmacokinetics of drugs used to
  • treat urge incontinence. Clin Pharmacokinet 1986: 42:
  • -1285.
  • Vereecken RL. A critical view on the value of
  • urodynamics in non neurogenic incontinence in women.
  • Int Urogynecol J 2000: 11: 188-195.
  • Coyne KS, Zyczynski T, Margolis MK, Elinof V,
  • Roberts RG. Validation of an overactive bladder
  • awareness tool for use in primary care settings. Adv
  • Ther 2005: 22: 381-394.
  • Hu TW, Wagner TH, Bentkover JD, et al. Estimated
  • economic cost of overactive bladder in the United
  • States. Urology 2003: 61: 1123-1128.
  • Abrams P, Anderson KE. Muscarinic receptor
  • anragonists for overactive bladder. BTU Int 2007: 100:
  • -1006.
  • Zinner M, Gittelman M, Haris R, et al. Trospium
  • chloride improves bladder symptoms. A multicenter
  • phase III trial. J Urol 2004:171: 2311-2315.
  • Rudy D, Cline K, Harris R, et al.Multicenter phase III
  • trial studying trospium chloride in patients with over
  • active bladder. Urology 2006; 67:275-280.
  • Halaska M, Ralph G, Wiedeman A, et al. Controlled,
  • double-blind, multicenter clinical trial to investigate
  • long-term tolerability and efficacy of trospium chloride
  • in patients with detrusor instability. World J Urol 2002:
  • : 392-399.
  • Flisser A, Walmsey K, Blavias JG. Urodynamics
  • classification of patients with symptoms of overactive
  • bladder. J Urol 2003: 169: 529-533.
  • Lin LY, Yeh NH, Lin CY, Sheu BC, Lin HH.
  • Comparisons of urodynamic characteristics between
  • female patients with overactive bladder and overactive
  • bladder plus stress urinary incontinence. Urology 2004:
  • : 945-949.
  • Digesu GA, Khullar V, Cardozo L, Stefano S.
  • Overactive bladder symptoms: Do we need
  • urodynamics? Neurourol Urodyn 2003: 22: 105-108.
  • Ouslander JG. Management of overactive bladder. N
  • Engl J Med 2004: 350: 786-799.
  • Staskin DR, Wein AJ, Andersson KE, et al. Overview
  • consensus statement. Urology 2003: 61: 1128-8.
  • Alloussi S, Laval KU, Eckert R, et al. Trospium chloride
  • in patients with motor urge symptoms: A double blind,
  • randomised, multicentre, placebo controlled study. J
  • Drug Asses 1999: 2: 27-39.
Toplam 81 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Bölüm Makaleler
Yazarlar

Cevdet Kaya

Abdullah İlktaç Bu kişi benim

Mustafa Güneş Bu kişi benim

Metin Öztürk Bu kişi benim

Hüseyin Kanberoğlu Bu kişi benim

Muhammet Karaman Bu kişi benim

Yayımlanma Tarihi 24 Haziran 2015
Yayımlandığı Sayı Yıl 2008 Cilt: 21 Sayı: 2

Kaynak Göster

APA Kaya, C., İlktaç, A., Güneş, M., Öztürk, M., vd. (2015). AŞIRI AKTİF MESANE SENDROMU OLAN KADINLARDA TROSPIUM CHLORIDE TEDAVİSİNİN ETKİNLİĞİ. Marmara Medical Journal, 21(2), 127-132.
AMA Kaya C, İlktaç A, Güneş M, Öztürk M, Kanberoğlu H, Karaman M. AŞIRI AKTİF MESANE SENDROMU OLAN KADINLARDA TROSPIUM CHLORIDE TEDAVİSİNİN ETKİNLİĞİ. Marmara Med J. Ağustos 2015;21(2):127-132.
Chicago Kaya, Cevdet, Abdullah İlktaç, Mustafa Güneş, Metin Öztürk, Hüseyin Kanberoğlu, ve Muhammet Karaman. “AŞIRI AKTİF MESANE SENDROMU OLAN KADINLARDA TROSPIUM CHLORIDE TEDAVİSİNİN ETKİNLİĞİ”. Marmara Medical Journal 21, sy. 2 (Ağustos 2015): 127-32.
EndNote Kaya C, İlktaç A, Güneş M, Öztürk M, Kanberoğlu H, Karaman M (01 Ağustos 2015) AŞIRI AKTİF MESANE SENDROMU OLAN KADINLARDA TROSPIUM CHLORIDE TEDAVİSİNİN ETKİNLİĞİ. Marmara Medical Journal 21 2 127–132.
IEEE C. Kaya, A. İlktaç, M. Güneş, M. Öztürk, H. Kanberoğlu, ve M. Karaman, “AŞIRI AKTİF MESANE SENDROMU OLAN KADINLARDA TROSPIUM CHLORIDE TEDAVİSİNİN ETKİNLİĞİ”, Marmara Med J, c. 21, sy. 2, ss. 127–132, 2015.
ISNAD Kaya, Cevdet vd. “AŞIRI AKTİF MESANE SENDROMU OLAN KADINLARDA TROSPIUM CHLORIDE TEDAVİSİNİN ETKİNLİĞİ”. Marmara Medical Journal 21/2 (Ağustos 2015), 127-132.
JAMA Kaya C, İlktaç A, Güneş M, Öztürk M, Kanberoğlu H, Karaman M. AŞIRI AKTİF MESANE SENDROMU OLAN KADINLARDA TROSPIUM CHLORIDE TEDAVİSİNİN ETKİNLİĞİ. Marmara Med J. 2015;21:127–132.
MLA Kaya, Cevdet vd. “AŞIRI AKTİF MESANE SENDROMU OLAN KADINLARDA TROSPIUM CHLORIDE TEDAVİSİNİN ETKİNLİĞİ”. Marmara Medical Journal, c. 21, sy. 2, 2015, ss. 127-32.
Vancouver Kaya C, İlktaç A, Güneş M, Öztürk M, Kanberoğlu H, Karaman M. AŞIRI AKTİF MESANE SENDROMU OLAN KADINLARDA TROSPIUM CHLORIDE TEDAVİSİNİN ETKİNLİĞİ. Marmara Med J. 2015;21(2):127-32.